Ask AI
ProCE Banner Activity

The French Revolution of HIV Care: Implementation of PrEP and Long-Acting ART

Conference Coverage
Clinical Thought

Oral PrEP has greatly reduced HIV incidence in men who have sex with men born in France, and the arrival of cabotegravir and lenacapavir on the French market will open new opportunities for convenient HIV treatments that increase quality of life without compromising efficacy. Here, I discuss key data from French studies regarding the implementation of these innovations in HIV care.

Released: March 18, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and other healthcare professionals who care for people living with or at risk of HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Appropriately apply and counsel patients regarding the clinical role(s) of new and investigational ART regimens and strategies

  • Devise HIV management strategies based on the results of recent clinical studies of established antiretroviral agents

  • Integrate the latest scientific findings to develop and optimize effective HIV prevention interventions

Disclosure

Primary Author

Karine Lacombe, MD, PhD: consultant/advisor/speaker: Gilead, Merck Sharp & Dohme, ViiV.